JP2010528008A - Ｃｄ３４幹細胞に関連した方法および組成物 - Google Patents

Ｃｄ３４幹細胞に関連した方法および組成物 Download PDF

Info

Publication number
JP2010528008A
JP2010528008A JP2010509362A JP2010509362A JP2010528008A JP 2010528008 A JP2010528008 A JP 2010528008A JP 2010509362 A JP2010509362 A JP 2010509362A JP 2010509362 A JP2010509362 A JP 2010509362A JP 2010528008 A JP2010528008 A JP 2010528008A
Authority
JP
Japan
Prior art keywords
subject
stem cells
genetically modified
cells
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010509362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528008A5 (enExample
Inventor
ラルフ フス
ピーター ネルソン
マッティアス ラッギ
マンフレート シュタングル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apceth GmbH and Co KG
Original Assignee
Apceth GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth GmbH and Co KG filed Critical Apceth GmbH and Co KG
Publication of JP2010528008A publication Critical patent/JP2010528008A/ja
Publication of JP2010528008A5 publication Critical patent/JP2010528008A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
JP2010509362A 2007-05-24 2008-05-20 Ｃｄ３４幹細胞に関連した方法および組成物 Pending JP2010528008A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93162207P 2007-05-24 2007-05-24
US305007P 2007-11-14 2007-11-14
PCT/US2008/006434 WO2008150368A1 (en) 2007-05-24 2008-05-20 Cd34 stem cell-related methods and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014007144A Division JP2014088432A (ja) 2007-05-24 2014-01-17 Ｃｄ３４幹細胞に関連した方法および組成物

Publications (2)

Publication Number Publication Date
JP2010528008A true JP2010528008A (ja) 2010-08-19
JP2010528008A5 JP2010528008A5 (enExample) 2011-07-07

Family

ID=40093981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010509362A Pending JP2010528008A (ja) 2007-05-24 2008-05-20 Ｃｄ３４幹細胞に関連した方法および組成物
JP2014007144A Pending JP2014088432A (ja) 2007-05-24 2014-01-17 Ｃｄ３４幹細胞に関連した方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014007144A Pending JP2014088432A (ja) 2007-05-24 2014-01-17 Ｃｄ３４幹細胞に関連した方法および組成物

Country Status (11)

Country Link
US (5) US7998472B2 (enExample)
EP (4) EP2229948B1 (enExample)
JP (2) JP2010528008A (enExample)
CN (2) CN103263439B (enExample)
AU (1) AU2008260651B2 (enExample)
BR (1) BRPI0811906A2 (enExample)
CA (1) CA2688032C (enExample)
DK (1) DK2223696T3 (enExample)
ES (3) ES2507507T3 (enExample)
PL (1) PL2162534T3 (enExample)
WO (1) WO2008150368A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
JP2017525364A (ja) * 2014-08-18 2017-09-07 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
KR102339760B1 (ko) 2007-07-23 2021-12-14 더 차이니즈 유니버시티 오브 홍콩 대규모 병렬 게놈 서열분석을 이용한 태아 염색체 이수성의 진단 방법
US12180549B2 (en) 2007-07-23 2024-12-31 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
US9393273B2 (en) 2008-05-27 2016-07-19 Pluristem Ltd. Methods of treating inflammatory colon diseases
CA2758120C (en) 2009-04-13 2014-08-19 Apceth Gmbh & Co. Kg Engineered mesenchymal stem cells and method of using same to treat tumors
US20110027239A1 (en) * 2009-07-29 2011-02-03 Tissue Genesis, Inc. Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9089550B2 (en) 2010-08-06 2015-07-28 Osaka University Combined islet transplantation using pancreatic islets and adipose tissue derived stem cells
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
EP3027235A1 (en) 2013-07-30 2016-06-08 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
AU2017242899A1 (en) * 2016-04-01 2018-07-05 Apceth Gmbh & Co. Kg Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy
CN110381982B (zh) * 2017-02-24 2023-11-28 得克萨斯州大学系统董事会 与myomixer促进的肌细胞融合相关的组合物和方法
EP3366303B1 (en) * 2017-02-28 2020-06-24 Martin-Luther-Universität Halle-Wittenberg Enhancing the targeted in vivo delivery of cellular therapies
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3807304A1 (en) 2018-06-15 2021-04-21 Children's Hospital Medical Center Polypeptides, nucleic acid molecules, compositions, and related methods
CN113164518B (zh) 2018-10-17 2025-06-24 森迪生物科学公司 组合癌症免疫疗法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006345726A (ja) 2005-06-14 2006-12-28 Hamamatsu Univ School Of Medicine 脳腫瘍治療用発現ベクター
WO2007037653A1 (en) 2005-09-29 2007-04-05 Ajou University Industry-Academic Cooperation Foundation Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20010038834A1 (en) * 1998-01-26 2001-11-08 Gary Balian Bone cancer therapy
US20030100107A1 (en) * 1998-05-29 2003-05-29 Thomas Jefferson University Compositions and methods for generating differentiated human cells
DE19833476B4 (de) * 1998-07-24 2005-08-25 Huss, Ralf, Dr. Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
US6866843B2 (en) * 1999-12-06 2005-03-15 Viacell, Inc. Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
US20030082155A1 (en) * 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
WO2002061033A2 (en) * 2000-11-27 2002-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transfection of human embryonic stem cells
US7268212B2 (en) * 2001-06-14 2007-09-11 Takeda Pharmaceutical Company Limited Ligand of G protein-coupled receptor protein and DNA thereof
WO2003010305A1 (en) 2001-07-27 2003-02-06 Arhus Amt Immortilized stem cells
WO2003025167A2 (en) * 2001-09-20 2003-03-27 Centre For Translational Research In Cancer Cultured stromal cells and uses thereof
WO2003087333A2 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2004007697A2 (en) * 2002-07-16 2004-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of implanting mesenchymal stem cells for tissue repair and formation
AU2003290601A1 (en) * 2002-11-05 2004-06-03 The Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
US20060216277A1 (en) * 2003-09-15 2006-09-28 Ramot At Tel Aviv University Ltd. Insulin-producing bone marrow derived cells and methods of generating and using same
EP1708757A4 (en) * 2003-12-19 2007-01-17 Viacell Inc USE OF PLURIPOTENTIAL CELLS TAKEN FROM HUMAN CORDIAL BLOOD BLOOD FOR THE TREATMENT OF DISEASE
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
DE602005017877D1 (de) * 2004-03-30 2010-01-07 Boston Scient Ltd Restenose-therapie mit mesenchym-stammzellen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006345726A (ja) 2005-06-14 2006-12-28 Hamamatsu Univ School Of Medicine 脳腫瘍治療用発現ベクター
WO2007037653A1 (en) 2005-09-29 2007-04-05 Ajou University Industry-Academic Cooperation Foundation Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013002613; Ｃｈｉｒｕｒｇｉｓｃｈｅｓ　Ｆｏｒｕｍ　ｆｕｅｒ　Ｅｘｐｅｒｉｍｅｎｔｅｌｌｅ　ｕｎｄ　Ｋｌｉｎｉｓｃｈｅ　Ｆｏｒｓｃｈｕｎｇ , 20070424, ｐ．１３-１５ *
JPN6013002614; Ｍｏｌｅｃｕｌａｒ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．４０，　臨時増刊号, 2003, ｐ．２４６-２５６ *
JPN7014001055; Ｍｏｌ　Ｔｈｅｒ，　２００７　Ａｐｒ　２４，　１５（７），　ｐ．１３７３-８１

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
JP2017093426A (ja) * 2012-02-01 2017-06-01 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
JP2017525364A (ja) * 2014-08-18 2017-09-07 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー 免疫細胞を惹起及び／又は活性化するための免疫応答刺激性サイトカインを発現する遺伝子改変型間葉系幹細胞

Also Published As

Publication number Publication date
US20160136207A1 (en) 2016-05-19
US7998472B2 (en) 2011-08-16
JP2014088432A (ja) 2014-05-15
EP2162534B1 (en) 2014-07-23
US20090041735A1 (en) 2009-02-12
EP2162534A1 (en) 2010-03-17
US20150238526A1 (en) 2015-08-27
US20150238541A1 (en) 2015-08-27
ES2507507T3 (es) 2014-10-15
EP2223696A1 (en) 2010-09-01
BRPI0811906A2 (pt) 2014-11-18
CA2688032C (en) 2015-11-03
CA2688032A1 (en) 2008-12-11
EP2229948A1 (en) 2010-09-22
AU2008260651B2 (en) 2014-06-12
EP2229948B1 (en) 2012-12-19
EP2851422A2 (en) 2015-03-25
HK1188735A1 (en) 2014-05-16
PL2162534T3 (pl) 2015-02-27
CN101778934A (zh) 2010-07-14
CN101778934B (zh) 2013-05-22
EP2223696B1 (en) 2013-07-10
EP2851422A3 (en) 2015-06-24
CN103263439A (zh) 2013-08-28
AU2008260651A1 (en) 2008-12-11
EP2162534A4 (en) 2010-09-22
ES2430071T3 (es) 2013-11-18
DK2223696T3 (da) 2013-10-07
HK1146488A1 (en) 2011-06-10
CN103263439B (zh) 2015-04-22
US20110268714A1 (en) 2011-11-03
ES2401608T3 (es) 2013-04-23
WO2008150368A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
JP2014088432A (ja) Ｃｄ３４幹細胞に関連した方法および組成物
Oggu et al. Gene delivery approaches for mesenchymal stem cell therapy: strategies to increase efficiency and specificity
Conrad et al. Genetically engineered stem cells for therapeutic gene delivery
Reiser et al. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases
EP3662915B1 (en) Mesenchymal stem cells and immunogens for use in inducing acquired immunological tolerance
CN1671836B (zh) 用于基因治疗的原代培养脂肪细胞
CA2779118A1 (en) Hypoxia regulated conditionally silenced aav expressing angiogenic inducers
Ebrahim et al. Genetic modification of mesenchymal stem cells for neurological disease therapy: what effects does it have on phenotype/cell behavior, determining their effectiveness?
JP2025520547A (ja) ＣＲＩＳＰＲ活性を調節するための操作Ａｃｒタンパク質
JP7144829B2 (ja) 安全性と抗炎症作用を高めた間葉系幹細胞
HK1188735B (en) Cd34 stem cell-related methods and compositions
Quenneville et al. Ex vivo modification of cells to induce a muscle-based expression
HK1146488B (en) Cd34 stem cell-related methods and compositions
CA2897188A1 (en) Cd34 stem cell-related methods and compositions
Shah et al. Genetic modification of adipose-derived stem cells for bone regeneration
EP4355879A2 (en) Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
Loperfido et al. PiggyBac transposons for stem cell-based gene therapy of Duchenne muscular dystrophy
Enhancer-Blocking RNA ViRus VectoRs
O'Connor Stem-Cell Therapy
Jung et al. Genetically Engineered Mesenchymal Stem Cells for Cell and Gene Therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130528

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140305

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140404